surmount 5 tirzepatide superior to Semaglutide- SURMOUNT-5 Trial Results A 3-year study of tirzepatide

Translational animal research conducted between 2025 and 2026 expanded the application of FOXO4-DRI into specialized rodent models of organ injury and tissue fibrosis

The peptide upregulates expression of epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor among others

[1] [2] For patients with documented hypersensitivity to other GLP-1 receptor agonists (such as semaglutide, dulaglutide, or liraglutide), cross-reactivity is uncertain due to differences in molecular structure

It has also been shown to reduce damage due to sunlight, reduce hyperpigmentation, and reduce the appearance of fine lines and wrinkles [1]